CLL
Conference Coverage
Consider treatment, testing when CLL symptoms emerge
CHICAGO – Predictive tests should be conducted before beginning therapy.
Conference Coverage
CLL: The initial work-up
CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.
Conference Coverage
Variant not linked to CLL in Southeast Europe
DUBROVNIK, CROATIA – The PTPN22 R620W polymorphism was not associated with CLL in patients from Southeast Europe.
News
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
From the Journals
Ibrutinib discontinuation harms survival in CLL
A single-institution study examines the impact of early dose reduction of ibrutinib in non-Hodgkin lymphoma and CLL.
News
Ibrutinib plus obinutuzumab gets priority review in CLL/SLL
This sets the stage for
Conference Coverage
Some mutation testing can be useful at CLL diagnosis
CHICAGO –
Conference Coverage
Novel options for treating hairy cell leukemia
NEW YORK –
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
News
FDA approves new drug for CLL/SLL and follicular lymphoma
Duvelisib (Copiktra) has full approval to treat CLL/SLL and accelerated approval to treat FL.
News
FDA approves new hairy cell leukemia drug
Moxetumomab pasudotox-tdfk (Lumoxiti) is approved to treat adults with relapsed or refractory hairy cell leukemia.